Sollte ich minoxidil succinoyl oligopeptide-143 in der Schwangerschaft meiden? | VeriMom

What to use instead

Pregnancy-safe ingredients that serve a similar function:

FAQ

Ist minoxidil succinoyl oligopeptide-143 in der Schwangerschaft sicher?

Minoxidil (6-(piperidinyl)-2,4-pyrimidinediamine-3-oxide) is listed as a substance that must not form part of the composition of cosmetics in EU Annexes (minoxidil and its salts appear in the prohibited list), which by your rules requires h≥2. Topical minoxidil is systemically absorbed in measurable amounts and there are case reports of effects in infants after dermal exposure; therefore a mechanism of systemic exposure is plausible. No SCCS/CIR opinion or harmonised H360/H361 specific to the peptide was found; evidence is via minoxidil data and regulatory prohibition. Sources: EU Annex listing, PubChem/minoxidil, EMA safety note on infant hypertrichosis.

Ist minoxidil succinoyl oligopeptide-143 während des Stillens sicher?

Minoxidil is a pharmacologically active systemic agent with reports of infant effects after maternal topical use and some evidence of transmission/infant exposure; regulatory guidance warns about infant hypertrichosis following skin contact. Thus breastfeeding safety is a concern (h=2). Mechanistic concern is demonstrated systemic exposure; measured transfer into milk is not well-quantified in public cosmetic dossiers, so exposure is graded as low but measurable for breastfeeding (e=1).

Ist minoxidil succinoyl oligopeptide-143 sicher für Babyhaut?

For dermal contact with infants (0–3 yr) there are case reports of excessive hair growth in infants after parental topical minoxidil use/contact, and infants have higher dermal uptake (immature barrier and higher surface-area-to-weight). Therefore hazard and mechanism scores follow minoxidil (h=2, m=2) and exposure is increased (adult e=2 → infant e=3 per your rules). No infant-specific toxicology studies for the peptide were found; the concern is driven by the minoxidil parent compound and case reports.

Wie bewertet VeriMom minoxidil succinoyl oligopeptide-143?

VeriMom bewertet minoxidil succinoyl oligopeptide-143 mit 33/100 (hohes Risiko) basierend auf EU CosIng, ECHA-Klassifizierungen und PubMed-Studien.

Was sind schwangerschaftssichere Alternativen zu minoxidil succinoyl oligopeptide-143?

Siehe unsere kuratierte Liste der schwangerschaftssicheren Alternativen zu minoxidil succinoyl oligopeptide-143 basierend auf ähnlicher Funktion.